News | January 03, 2023
Blacksmith announces merger with Forge Therapeutics
To create leading company developing medicines targeting metalloenzymes
To create leading company developing medicines targeting metalloenzymes
To focus on providing safer burn treatments for women and armed forces
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Orion to receive an upfront payment of USD 290 million
Subscribe To Our Newsletter & Stay Updated
